People channel feed

Sue Desmond-Hell­mann joins the mar­quee crowd of bio­phar­ma ex­perts at GV boot­ing up a new gen­er­a­tion of drug hunters

6 years ago

Eli Lil­ly ex­ecs have been think­ing about the longterm ef­fects of the pan­dem­ic and dam­age con­trol. Here’s what they be­lieve

6 years ago
R&D
Coronavirus

Bio­gen’s top ex­ec­u­tive crew has a big cred­i­bil­i­ty is­sue. And they seem de­ter­mined to make it worse

6 years ago
Bioregnum
Opinion

De­posed BAR­DA chief blasts Trump ad­min­is­tra­tion on pro­mot­ing un­proven drugs as Covid-19 panacea: 'Science — not pol­i­tics or crony­ism — has to lead the way'

6 years ago
Coronavirus

A long­time Lau­ra Shawver fan calls the se­r­i­al en­tre­pre­neur back to the helm of a biotech up­start

6 years ago
Startups

BAR­DA chief leaves po­si­tion as agency en­ters un­prece­dent­ed vac­cine cam­paign, rais­ing ques­tions about fed­er­al Covid-19 re­sponse

6 years ago
Coronavirus

Still no ad­u­canum­ab fil­ing and an in-house gath­er­ing trig­gered a health dis­as­ter, but Bio­gen's CEO nev­er­the­less took home record pay

6 years ago

It’s not the mon­ey: The lat­est For­tune list of the top 10 bio­phar­mas to work for in­cludes a few sur­prise play­ers

6 years ago

Pas­cal So­ri­ot, lamenter of low pay, faces in­vestor re­volt for be­ing over­com­pen­sat­ed

6 years ago

Phar­ma­cyclics bil­lion­aire Bob Dug­gan takes the helm of an­oth­er biotech — and he faces an even big­ger up­hill climb this time

6 years ago

Q&A: An­a­lyst-turned biotech ex­ec-turned an­a­lyst reads the biotech Q1 tea leaves

6 years ago
R&D
Pharma

Bio­phar­ma bil­lion­aires dom­i­nate Forbes' list of the world's top 10 wealth­i­est health­care ex­ecs — and the pan­dem­ic has­n't hurt

6 years ago

Ready to de­clare a de­fin­i­tive come­back in two months, Im­munomedics stops PhI­II ear­ly, re­cruits new CEO

6 years ago
R&D

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

6 years ago
Special

Mo­tion de­nied: Gilead still on the hook for $1.5B in dam­ages over CAR-T patent dis­pute with Bris­tol My­ers Squibb

6 years ago
Cell/Gene Tx

How to build CAR–M: Carl June pro­tégé and his biotech pub­lish first ev­i­dence in Na­ture Biotech­nol­o­gy

6 years ago
Discovery
Cell/Gene Tx

Do­ing deals in a time of coro­n­avirus: Biotech CEO Bill Haney says 'y­ou fo­cus on the things that make a dif­fer­ence'

6 years ago
Deals
Coronavirus

GSK qui­et­ly re­veals just how much cash they used to buy a chunk of the Bay Area's buzzi­est start­up

6 years ago
Deals
R&D

Bris­tol My­ers CEO Caforio hires a top in­vest­ment banker from Bar­clays for his next BD/strat­e­gy chief

6 years ago

‘Pa­tient ze­ro’ in Ten­nessee talks about fear, anx­i­ety, hys­te­ria and count­less acts of kind­ness as the Bio­gen out­break spreads

6 years ago
Coronavirus

Five days af­ter re­gain­ing the helm at Cure­Vac — and 1 day af­ter con­tro­ver­sy erupt­ed — In­g­mar Ho­err makes sur­prise ex­it

6 years ago

Bio­gen staffer fled to Chi­na in search of emer­gency Covid-19 test­ing, care — and now faces crim­i­nal charges

6 years ago
Coronavirus

Biotech en­tre­pre­neurs Arie Bellde­grun and Cedric Fran­cois test pos­i­tive for Covid-19 — and here's why they want you to know

6 years ago
Coronavirus

Vir’s George Scan­gos teams up with his for­mer col­leagues at Bio­gen to press fast-for­ward on an­ti­body pro­grams for coro­n­avirus

6 years ago
R&D
First page Previous page 69707172737475 Next page Last page
A service from the Financial Times